Tempest Therapeutics (TPST) Price & Analysis

Compare

1,257 Followers

TPST Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.35 - $28.34

Previous CloseN/A

Volume2.28M

Average Volume (3M)83.17K

Market Cap

$30.21M

Enterprise Value$24.58M

Total Cash (Recent Filing)$21.51M

Total Debt (Recent Filing)$13.11M

Price to Earnings (P/E)―

Beta1.97

Next Earnings

Nov 05, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding4,087,428

10 Day Avg. Volume113,206

30 Day Avg. Volume83,165

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.81

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.56

Forecast

1Y Price Target

$9.00

Price Target Upside28.02% Upside

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

EarningsTempest posted EPS of ($3.16), which was better than both the analyst's estimate and the consensus estimate.

FDA ApprovalTempest recently held a successful EOP2 meeting with the FDA, reaching a broad agreement on the Phase 3 study plan, including dose schedule and primary endpoint.

PartnershipsThe recent drug supply agreement with Roche will supply atezolizumab for the upcoming Phase 3 study, providing a significant cost savings for the company.

Bears Say

Funding ChallengesTempest will still require a sizable cash infusion to fully support Phase 3 development, with management indicating it would cost approximately $100 million.

Market ConditionsVery deep frustration with Tempest's position due to the timing of data from Roche's MORPHEUS-Liver study and unprecedented conditions of the financial markets for healthcare funding.

Tempest Therapeutics News

Tempest Therapeutics, Inc. (TPST) Q2 Earnings Cheat Sheet

Tempest Therapeutics, Inc. (TPST) is scheduled to report 2nd quarter earnings on 08/07/2025. Regarding Q2 estimates, Wall Street...

4d ago

TPST

Morpheus-Liver Study: A New Horizon in Advanced Liver Cancer Treatment

Tempest Therapeutics, Inc. (($TPST)) announced an update on their ongoing clinical study. The Morpheus-Liver study, officially titled A...

4d ago

TPST

Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment

Tempest Therapeutics, Inc. (($TPST)) announced an update on their ongoing clinical study. The clinical study titled A Study...

1M ago

TPST

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

Tempest Therapeutics (TPST) announced that the company received approval from the National Medical Products Administration in China to...

1M ago

TPST

Tempest Therapeutics Secures $4.1M in Direct Offering

The latest update is out from Tempest Therapeutics ( ($TPST) ). On June 11, 2025, Tempest Therapeutics entered...

2M ago

TPST

Tempest prices 739,000 shares at $6.25 in registered direct offering

Tempest Therapeutics (TPST) has entered into a definitive agreement with a single institutional investor for the purchase and...

2M ago

TPST

Tempest Therapeutics Shifts Executives to Consulting Roles

Tempest Therapeutics ( ($TPST) ) has issued an announcement. Tempest Therapeutics announced a strategic shift on June 5,...

2M ago

TPST

Tempest Therapeutics receives ODD from EMA for amezalpat

Tempest Therapeutics (TPST) announced that the European Medicines Agency, EMA, has granted Orphan Drug Designation, ODD, to amezalpat,...

2M ago

TPST

Tempest Therapeutics Reports Q1 2025 Financial Results

Tempest Therapeutics, Inc. ( ($TPST) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

TPST

Tempest Therapeutics: Navigating Financial Challenges with Promising Clinical Data and Strategic Partnerships

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on TPST stock, giving a Hold rating yesterday....

3M ago

TPST

Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)

“The amezalpat program continues to produce data that reinforce its potential as a cancer therapy, most recently in...

3M ago

TPST

Cautious Optimism for Tempest Therapeutics Amid Strategic Reorganization and Promising Amezalpat Data

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on TPST stock, giving a Hold rating on...

3M ago

TPST

Tempest Therapeutics announces FDA granted ODD to TPST-1495

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation, ODD, to...

4M ago

TPST

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

ADTX

CRMD

TPST FAQ

What was Tempest Therapeutics’s price range in the past 12 months?

Tempest Therapeutics lowest stock price was $5.35 and its highest was $28.34 in the past 12 months.

What is Tempest Therapeutics’s market cap?

Tempest Therapeutics’s market cap is $30.21M.

When is Tempest Therapeutics’s upcoming earnings report date?

Tempest Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 88 days.

How were Tempest Therapeutics’s earnings last quarter?

Currently, no data Available

Is Tempest Therapeutics overvalued?

According to Wall Street analysts Tempest Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tempest Therapeutics pay dividends?

Tempest Therapeutics does not currently pay dividends.

What is Tempest Therapeutics’s EPS estimate?

Tempest Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tempest Therapeutics have?

Tempest Therapeutics has 4,087,428 shares outstanding.

What happened to Tempest Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tempest Therapeutics?

Currently, no hedge funds are holding shares in TPST

Tempest Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-282.07%

Trailing 12-Months

Asset Growth

-27.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tempest Therapeutics

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Tempest Therapeutics (TPST) Earnings & Revenues

Historic Earnings Reports

TPST Stock 12 Month Forecast

Average Price Target

$9.00

▲(28.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","38":"$38","71":"$71","21.5":"$21.5","54.5":"$54.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,21.5,38,54.5,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.015384615384615,7.18076923076923,7.346153846153846,7.5115384615384615,7.676923076923076,7.842307692307692,8.007692307692308,8.173076923076923,8.338461538461539,8.503846153846155,8.669230769230769,8.834615384615384,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.015384615384615,7.18076923076923,7.346153846153846,7.5115384615384615,7.676923076923076,7.842307692307692,8.007692307692308,8.173076923076923,8.338461538461539,8.503846153846155,8.669230769230769,8.834615384615384,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.015384615384615,7.18076923076923,7.346153846153846,7.5115384615384615,7.676923076923076,7.842307692307692,8.007692307692308,8.173076923076923,8.338461538461539,8.503846153846155,8.669230769230769,8.834615384615384,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.1,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.91,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.84,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.72,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.06,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.16,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.23,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.29,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >